---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-039285"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T01:07:53.657665+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data

## Summary
- Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.
- Cash, equivalents, and marketable securities $79.6M at June 30, up from $19.2M Dec 31, 2020.
- Preclinical data for LP-184 showed 93% avg tumor volume reduction in pancreatic cancer models.
- Preparing LP-300 Phase 2 trial site selection and GMP batch for NSCLC in Q3 2021.
- Reacquired LP-100 (Irofulven) rights from Allarity; $1M upfront plus up to $16M milestones.

## SEC filing metadata
- accession: 0001213900-21-039285
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000121390021039285/0001213900-21-039285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000121390021039285/ea144935-8k_lanternpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-039285
- JSON: https://secwatch.observer/filing/0001213900-21-039285.json
- Plain text: https://secwatch.observer/filing/0001213900-21-039285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.